Skip to main content

Animations

MJFF Publications

4011 - 4020 of 6568 Results
Title
Year
  • Year
  • 2025
  • 2025
  • 2009
  • 2021
  • 2018
  • 2011
  • 2005
  • 2015
  • 2025
  • 2018
  • Summary Details
    OPEN
    Title: Magnetoelectric nanoparticle technology for mitigating motor deficits in Parkinsonian mice
    Journal Name: Brain Stimulation
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.brs.2025.08.008
    Citation Count: 4
  • Summary Details
    OPEN
    Title: GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1126/sciadv.adv1434
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0b013e3181c29356
    Citation Count: 430
  • Summary Details
    OPEN
    Title: Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00214-3
    Citation Count: 599
  • Summary Details
    OPEN
    Title: Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-171248
    Citation Count: 308
  • Summary Details
    OPEN
    Title: Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(11)70175-2
    Citation Count: 344
  • Summary Details
    OPEN
    Title: Paraquat Neurotoxicity is Distinct from that of MPTP and Rotenone
    Journal Name: Toxicological Sciences
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/toxsci/kfi304
    Citation Count: 270
  • Summary Details
    OPEN
    Title: Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.26170
    Citation Count: 307
  • Summary Details
    OPEN
    Title: Virtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators
    Journal Name: Journal of Chemical Information and Modeling
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1021/acs.jcim.5c00972
    Citation Count: 2
  • Summary Details
    OPEN
    Title: The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20180248
    Citation Count: 219
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.